Pharmaceutical continuous manufacturing: what’s next for industry?
Supported by:
1 August 2024
2:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
During this virtual panel, industry experts will discuss adoption of continuous manufacturing in the pharmaceutical industry.
Register your place today.
Pharmaceutical continuous manufacturing (PCM) is an advanced technology that processes inputs and materials on a continuous basis in contrast with batch processing that is more sequential by nature. It offers a range of benefits – economic, environmental, and more – over traditional batch manufacturing, for both small molecules and biologics.
Studies suggest the use of continuous processes for facilities producing oral solid dosage (OSD) formulations is less labour intensive, more efficient and could lead to more consistent product quality. Investing in CM can also reduce disruptions in the flow of drugs during global risk events, like the COVID-19 pandemic.
In the biologics space, too, there is increased interest in the use of continuous bioprocesses. A recent study predicted that end-to-end continuous manufacturing of monoclonal antibodies (mAbs) could be 20-40 percent more cost effective than batch processes.
But is PCM a viable commercial proposition?
In this session, speakers will draw on their own experiences and strategies implementing continuous manufacturing processes for a range of drug products and drug substances. The panel will also explore the benefits, challenges and opportunities for increasing adoption of CM across the pharmaceutical industry.
Discussion points:
- The economics of CM over batch manufacturing
- Strategies and approaches for implementing continuous processes
- Benefits and challenges of pharmaceutical continuous manufacturing
- Regulatory and market outlook.
OUR SPEAKERS
Moderator: Clifford Rossi – Professor, University of Maryland
Clifford Rossi is a Professor of the Practice and Executive-in-Residence at the Robert H. Smith School of Business, University of Maryland. Before joining academia, he spent 25‑plus years in the financial sector, as both a C-level risk executive at several top financial institutions and a federal banking regulator. He is the former managing director and CRO of Citigroup’s Consumer Lending Group.
Irina Ramos, PhD – Director, AstraZeneca
Irina Ramos is a director of downstream continuous manufacturing, in the Bioprocess Engineering and Technology group at AstraZeneca in Gaithersburg, MD, USA. She has been a key driver of the technology development and implementation strategy for continuous biomanufacturing. Irina holds a BS/MS in Chemical Engineering from University of Porto (Portugal) and a PhD in Chemical & Biochemical Engineering from University of Maryland, Baltimore County (UMBC).
Sripathy Venkatraman – VP, Head of Global R&D Operations at Curia
Sripathy Venkatraman is Curia’s Vice President and Head of R&D Global Operations. He has over 25 years of experience in the healthcare sector, leading global R&D teams in the development of Drug Substance and Drug Products. He has been with Curia for the past 21 years with the majority of his experience in the small molecule space. Sripathy holds a PhD in Organic Chemistry from the Tulane University and an MBA from University at Albany (SUNY).
Jan-Sebastiaan Uyttersprot – Head of Manufacturing and Powder Technology, UCB
Sebastiaan is leading the Manufacturing & Powder Technologies group, which is accountable for development and manufacture of drug products from preclinical and clinical development and scale-up to the commercial phase, including Process Analytical Technology (PAT) and digital twin development. Before joining UCB (2020), he worked as a data scientist for Indigomed, designing an implantable NIR sensor to monitor metabolites for chronic diseases. Sebastiaan started his career in Procter & Gamble, and during the last 10 years at P&G, he founded the PAT department that developed for all product categories in and atline applications around the globe.
FAQs
FAQs
Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.
When will the webinar take place?
1 August 2024 at 3.00pm GMT.
Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the webinar be?
This webinar will last up to an hour.
What do I need to watch this webinar?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.
